With the advent of high content screening methodologies (e.g. cellular imaging, transcriptomics, etc.), it becomes more challenging to tease apart and visualize batch effects. This is further compounded when building machine learning models which can easily use these confounding variables instead of real biological signal to generate predictions leading to poor real world relevance.
Advocate for healthcare technology innovation joins BioSymetrics in a mission to empower the application of AI within biomedicine.
NEW YORK, February 7, 2019 (GLOBE NEWSWIRE) – BioSymetrics, an artificial intelligence and machine learning SaaS company, announces Dr. Calum MacRae as Senior Advisor. Dr. MacRae is an innovative pioneer in genetics, biology, and drug discovery. With his deep knowledge and expertise, Dr. MacRae will assist BioSymetrics in the design and application of the company’s software for use in drug discovery, precision medicine and health systems.
“The introduction of AI into medicine is challenged by a fundamental defect of information content and standards,” said Dr. Calum MacRae. “BioSymetrics is leading the promise that we are entering an era in which precision medicine and AI finally attain real world applications; overcoming a number of AI challenges across a wide spectrum of biomedicine.” Continue Reading